Bill Lundberg, M.D., has stepped down as CSO of CRISPR Therapeutics. News of Lundberg’s departure emerged on the same day Celgene revealed it has sold another chunk of its once-double-digit stake in the CRISPR/Cas9 gene editing startup.
A new long-acting reversible contraception method offering protection from unplanned pregnancy for up to five years has been launched in the UK.
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
A vast majority of accountable-care organizations in zero-risk contracts would reap additional savings if they took on downside risk because of the bonuses incurred as an advanced alternative payment model under MACRA, a new analysis finds.
Materials are one of the most common causes of failure in medical devices, especially for plastic. Records show that material failure is responsible for 30 to 40 percent of all FDA recalls on medical devices.
Cultivating a strong relationship with patients can translate into higher satisfaction scores but there is a widespread failure to communicate about the most appropriate way to reach consumers.
Human eggs have been fully grown in a laboratory for the first time in what has been hailed as a majorfertility breakthrough.
Genentech’s PD-L1 inhibitor Tecentriq continues to show off its versatility. Monday, the Roche subsidiary announced a combination of Tecentriq and Avastin (bevacizumab) was significantly beneficial to patients with advanced or metastatic renal cell carcinoma (mRCC) who have not received prior systemic active or experimental therapy.
Scientists have uncovered a key mechanism that facilitates the spread of breast cancer cells, and thus a potential target for new therapeutic approaches in the fight against the disease.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a first-in-class oral, gastrointestinal (GI) restricted pan-Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis (UC).
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.